"Contakt World: Truth in Health" Podcast Unveils Sixth Episode - Featuring In-Depth Interviews with Emmy Award-Winning Journalist, Dr. Seema Yasmin, and Retired Olympic Distance Runner, Kemoy Campbell, Entitled "Likes, Clicks, Faves vs Saving Lives"

Tracker Ventures Corp. ("Tracker" or the "Company") (CSE:TKR)(OTC PINK:TLOOF)(FWB:B2I) announced that Contakt LLC ("Contakt World"), a technology company modernizing public health and safety, has released the sixth episode of the "Contakt World: Truth in Health" podcast. The podcast is available on iHeartRadio and other popular streaming sites for podcasts

Listen Now Here

"Many people are unaware of the physical and mental consequences a viral infection can have on the body, if it is avoided and not properly taken care of," said Deepti Pahwa, Chief Innovation Officer of Contakt World and co-host of the podcast. "The first half of this episode highlights Kemoy Campbell who watched his long-distance running career end right before his eyes due to a viral infection and his advice to athletes on how to take care of themselves during the pandemic."

"The second part of our episode highlights the constant information and misinformation surrounding the pandemic that clouds our social media channels and plays a significant impact on people's knowledge about public health," said Justin Beck, Founder and CEO of Contakt World. "This is a major issue in today's society that needs to be addressed, and we were honored to discuss this topic with Dr. Seema Yasmin, pinpointing how to restore trust from past and current instances of medical racism and how to be mindful of the information we choose to share on our individual platforms."

A description of the sixth episode can be found below.

"Contakt World: Truth in Health" Podcast

Episode 6: Likes, Clicks, Faves vs Saving Lives

"Who's right? And furthermore, who decides what is right? It's the fundamental question of our times, not only in terms of ethics, but also systems of information. In this age of COVID, misinformation and social media, there's a lot to contend with. So, how do we navigate it? Join our hosts Justin Beck, Catherine Delcin and Deepti Pahwa, as they speak with Dr. Seema Yasmin, an Emmy Award-winning journalist, poet, medical doctor and author who discusses the direct effects of Facebook on public health. We also hear from Kemoy Campbell, a retired Olympic distance runner from Jamaica, who educates athletes on the importance of heart health, and how to properly listen to your body, especially in the age of COVID. As always, we'll talk about how to help our local health departments - and encourage innovation and technology integration - all while remaining empathetic, plus keeping an eye toward health equity for all."

"Contakt World: Truth in Health" is distributed by the iHeartPodcast Network and also available on Apple and Spotify. For video previews, highlights and full-length episodes, please visit Contakt World on YouTube.

* No content within or related to this podcast has been evaluated by the FDA. Any information presented by Contakt World or its guests is not intended to treat or cure any disease, and no claims are made as to the accuracy or sufficiency thereof.

Contakt World - Tracker Transaction

Tracker and Contakt World are parties to a definitive amalgamation agreement pursuant to which Tracker will indirectly acquire (the "Acquisition") a 100% interest in Contakt World. For further information respecting the Acquisition, please refer to the Company's news release dated December 8, 2020. Trading of Tracker's shares on the Canadian Securities Exchange (the "CSE") has been halted in connection with the announcement of the Acquisition and is not expected to resume until the CSE has approved a Form 2A Listing Statement for the resulting issuer from the Acquisition. There can be no assurance that the Acquisition will be completed on the terms proposed in the amalgamation agreement or at all.

About Contakt World

Contakt World is a technology and media company innovating public health agency connections with their community, with the goal of becoming the most trustworthy, accessible and scalable digital public health and safety platform globally - addressing the needs of a post-pandemic world. Contakt World combines aggressive research and development, human-centered design, next-gen data integrations, and strategic health partnerships to empower and build mutual trust within communities, contributing towards health equity for users around the world. Contakt World's first suite of tools emerge from the urgency surrounding coronavirus to manage the pandemic through innovative contact tracing and case management spanning multiple modes of communication. For more information, please visit the Company's website at www.contakt.world.

Tracker Ventures Contact
Geoff Balderson
CEO and Director
Direct: 604-602-0001

Media Contact
Kevin Harrington
Account Director - 5WPR
contaktPR@5wpr.com

Investor Contact
Lucas A. Zimmerman
Senior Vice President - MZ North America
Direct: 949-259-4987
contakt@mzgroup.us
www.mzgroup.us

The CSE has not reviewed, approved or disapproved the content of this news release.

SOURCE:Tracker Ventures Corp.



View source version on accesswire.com:
https://www.accesswire.com/634505/Contakt-World-Truth-in-Health-Podcast-Unveils-Sixth-Episode--Featuring-In-Depth-Interviews-with-Emmy-Award-Winning-Journalist-Dr-Seema-Yasmin-and-Retired-Olympic-Distance-Runner-Kemoy-Campbell-Entitled-Likes-Clicks-Faves-vs-Saving-Lives

News Provided by ACCESSWIRE via QuoteMedia

The Conversation (0)
Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") announces results from its most recent preclinical study of its Targeted Hyperthermia Therapy ("THT") which uses the Company's patented, biocompatible gold nanorods ("GNRs") to treat certain solid cancer tumors, shrinking them and acting as an immune stimulator. Building on its success in melanoma and breast cancer studies, the Company's third preclinical efficacy study was conducted in an immunologically 'cold' colorectal cancer model ("CT26"), a model that represents the majority of human colon cancers, which do not typically respond to current standard of care immunotherapies.

In this preliminary study, whereas no mice that were given standard immunotherapy alone showed any response, 100% of mice in the THT treatment group responded to the same immunotherapy with 50% (4 out of 8) of those tumors eliminated within 12 days of treatment, as shown by the green line in Figure 1, below.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is pleased to announce the establishment of its new Advisory Board. The Advisory Board will collaborate with management and the board of directors to enhance the Company's strategic direction, provide expert guidance on its commercial initiatives, offer industry insights, and shape and accelerate innovations.

As the inaugural member of the Advisory Board, Syntheia welcomes Mr. John Kirk, a leader in the travel industry. The travel sector represents a potentially significant growth market for the Company's technology.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is transforming customer service by delivering an innovative solution that uses natural language processing (NLP) to handle inbound telephone calls with virtual assistants. Since its beta launch in June 2023, Syntheia has processed over 750,000 conversations, bringing new levels of efficiency and engagement to businesses in diverse industries.

Companies like Georgetown Hyundai, Palmieri Furniture, Campio Furniture, and Pay N Go have all embraced Syntheia's platform, highlighting its positive impact on sales and customer satisfaction.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Zero Candida Technologies Inc.  Opens the Market

Zero Candida Technologies Inc. Opens the Market

Eli Ben-Haroosh, Co-Founder and Chief Executive Officer, Zero Candida Technologies Inc. (TSXV: ZCT) ("Zero Candida" or the "Company"), joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange, to open the market to celebrate the Company's new listing on the TSX Venture Exchange.

Zero Candida Technologies, Inc. (ZCT), is a medical device company bringing female healthcare into the 21st century. They are transforming the treatment of Vulvo-Vaginal Candidiasis ("VVC"), which affects 75% of women worldwide, often recurrent and increasingly drug-resistant with current treatments failing to address the root cause effectively. Free from chemicals and side effects, their AI-driven tampon-like device enables real-time data collection and transmission to physicians for personalized, at-home treatment. Beyond VVC, ZCT aims to revolutionize gynecology, improving access for underserved populations and advancing hybrid medicine.

Please refer to the Company's website here.

MEDIA CONTACT:
Victoria Gamble
Corporate Development Consultant
victoria@zero-candida.com
416-706-0332

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231280

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
XReality Group

xReality Group Limited Chairman’s Address 2024 Annual General Meeting – 22 November 2024

xReality Group Limited (ASX:XRG) (xReality) is pleased to present xReality Group Limited’s 2024 Annual General Meeting.

Keep reading...Show less
XReality Group

Operator XR – Sales Update November 24

xReality Group Limited (ASX:XRG) (xReality) is pleased to provide the following sales update for Operator XR, a wholly owned subsidiary of xReality Group Ltd. Operator XR provides Military and Law Enforcement agencies around the world with a unique, integrated Mission Planning & Rehearsal System, which is portable, secure, and highly immersive.

Keep reading...Show less

Latest Press Releases

Related News

×